Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,864 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Escondido, California • La Jolla, California • San Mateo, California + 16 more

Conditions: Advanced Non-hematologic Malignancies
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more

Conditions: Tic Disorder, Childhood, Comorbidities and Coexisting Conditions
Interventions: Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training); Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Failure
Interventions: Medtronic Pacemaker; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Occupational Therapy, Activities of Daily Living, Rehabilitation, Virtual Reality
Interventions: VALOR Home Exercise Program (HEP), Usual Care Treatment (UCT) Control; Device · Other
Lead sponsor: Barron Associates, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections, Alcohol Use Disorder, Violence, Gender-Based
Interventions: PrEP for WINGS, PrEP Decision Aid; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Anemia, Renal Insufficiency, Chronic
Interventions: Mircera; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Loma Linda, California • Atlanta, Georgia + 4 more

Conditions: Type 1 Diabetes (T1D)
Interventions: Cadisegliatin 800 mg QD, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypoxic-Ischemic Encephalopathy
Interventions: Holding during cooling; Other
Lead sponsor: Alexa Craig; Other
Eligibility: 24 Hours to 3 Days
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Diabetes Mellitus, Type II
Interventions: Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Concord, California • Encino, California • Escondido, California + 18 more

Conditions: Genital Herpes
Interventions: AIC316, Valacyclovir; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Indianapolis, Indiana • Portland, Oregon • Houston, Texas + 1 more

Conditions: Head and Neck Cancer
Interventions: Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel; Radiation · Drug · Biological
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pediatric Asthma
Interventions: School-Based Telemedicine Enhanced Asthma Management, Enhanced Usual Care; Other
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 10 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Diego, California

Conditions: Spinal Cord Injuries
Interventions: Qigong; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sphingomyelin Lipidosis
Interventions: GZ402665; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment; Drug
Lead sponsor: Clinical Research Center of the Carolinas; Other
Eligibility: 2 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Substance Use Disorders, Pain
Interventions: SBIRT-PM; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Opioid Misuse, Trauma Injury
Interventions: Opioid Risk Monitoring (ORM), enhanced Trauma Care Coordination (eTCC), Pain Coping Skills Training - Brief (PCST-LITE), Standard Trauma Care Coordination (sTCC), Pain Coping Skills Training - Plus (PCST+), Pain Coping Skills Training - Maintenance (PCST-M); Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Infertility, Female
Interventions: Diet Intervention - Group 1, Exercise Intervention - Group 1; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 21 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Stress Disorders, Post-Traumatic, Bulimia Nervosa
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Glioblastoma
Interventions: Depatuxizumab mafodotin, Temozolomide, Lomustine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 99 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more

Conditions: Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions: Ethosuximide, Lamotrigine, Valproic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 30 Months to 13 Years
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more

Conditions: Inflammatory Bowel Diseases
Interventions: Biofeedback Enhanced Treatment; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Search by objective public record fields.

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Improving Symptom Trajectories of Tic Disorders and Co-occurring Diagnoses: The Role of Integrative Intensive Intervention

Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate

Virtual Activities of Living for Occupational Rehabilitation

An Effectiveness Trial of the PrEP for WINGS Study

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

Holding, Stress, and Bonding During Therapeutic Hypothermia

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

School-Based Telemedicine Enhanced Asthma Management

Oral Testosterone for the Treatment of Hypogonadism in Males

CREATION: A Clinical Trial of Qigong for Neuropathic Pain Relief in Adults With Spinal Cord Injury

A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Pilot of Pragmatic SBIRT Study

Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention

The MOM TO BE Study

Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Heart Rate Variability and Inflammatory Bowel Disease